HomeTechnologyAbout Us
Connect With Us
© 2025 Adaptyx.
All rights reserved.
© 2025 Adaptyx. All rights reserved.
Privacy PolicyTerms of Service

We're making the invisible, visible – continuously.

Learn More
The Breakthrough
For decades, continuous biochemical monitoring meant one thing: glucose. The rest of human biochemistry – hormones surging, drugs metabolizing, proteins signaling – remained invisible between lab visits.
We're changing that.
Our programmable molecular switches can detect virtually any molecule in your body, continuously, in real-time. This changes how we capture human biochemistry.
How Our Programmable Molecular Switches Work
At the core of our platform are programmable molecular switches – proprietary synthetic DNA architectures that go beyond conventional aptamers. Unlike traditional aptamer-based sensors, our switches are engineered from the ground up to recognize specific target molecules with tunable performance.
Upon binding, the switch undergoes a conformational change that produces a measurable signal in real time.
Upon binding, the switch undergoes a conformational change that produces a measurable signal in real time.
This simple, elegant mechanism is the foundation for a new class of biosensors: modular, tunable, and built for continuous molecular monitoring.
This simple, elegant mechanism is the foundation for a new class of biosensors: modular, tunable, and built for continuous molecular monitoring.
Molecular switch development that once took years now takes weeks
Beyond Glucose: A Platform for Any Molecule
Unlike enzyme-based systems, which are limited to a few privileged analytes, our molecular switches can be built for nearly any molecule:
Metabolites
Lactate, creatinine, urea
Drugs
Chemotherapy agents, antibiotics, immunosuppressants
Electrolytes
Potassium, sodium, magnesium, calcium
Proteins
Cytokines, cardiac markers, hormones
And More.....
What This Enables Today
Precision drug dosing to remain in therapeutic windows, ensuring drug efficacy and reducing side effects
What This Enables Today
Precision drug dosing to remain in therapeutic windows, ensuring drug efficacy and reducing side effects
The Switch Foundry
Where Years Become Weeks
The Switch Foundry is our high-throughput engine for engineering molecular switches at unprecedented speed and scale.
1
Automated Biomolecular Engineering
2
Massively-Parallel Screening
3
Computational & AI-assisted Design
Traditional Approach
Black-box screening
Trial and error
Years per sensor
Limited learning between attempts
Our Approach
Systematic, data-driven design
Parallel optimization
Weeks per sensor
Every experiment improves the next
50x
faster development
10,000x
more data per cycle
The Data-Intelligence Flywheel
Every switch we build generates structured, high-quality experimental data — binding affinity, kinetics, specificity, and signal performance. These data are not just byproducts — they are fuel.
Our standardized process creates massive, consistent datasets that train machine learning models to predict and optimize new switch designs.
The more we build, the smarter we get. The smarter we get, the faster we build.
Built for the Real World
Where Others Fail, We Thrive
Robust Performance in Interstitial Fluid
Resistant to biofouling
Stable for weeks
Maintains accuracy in complex biological matrices
Programmable Dynamic Range
Picomolar to millimolar detection
Tunable thermodynamics & kinetics for each switch
Optimized for physiological conditions
Our Scientific Foundation
A Decade of Stanford Innovation
Led by our co-founders, Professors Tom Soh and Joseph M. DeSimone, our team has pioneered the field of continuous molecular monitoring.
9
Patent Families
50+
Publications
$20M+
Research Funding
2009
Aptamer-based switch used for continuous and real-time monitoring of cocaine in undiluted serum1
2013
First in vivo demonstration: real-time, aptamer-based therapeutic sensing in rats2
2014
Particle display aptamer-selection technology developed3
2017
Closed-loop automated drug dosing demonstrated in animal models4
2019
Methods for programmatically tuning molecular switches5
2021
Base-modified aptamers developed against challenging glycan targets6
2022
Multiplexed method for developing highly specific aptamers developed7
2022
Perspective published on utility of ISF as a diagnostic fluid8
2022
3D-Printed Microarray Patches9
2023
Massively parallel molecular switch screening platform10
2023
High throughput method for optimizing molecular switches for physiological conditions11
2023
Various next generation molecular switch scaffolds developed12,13,14
References
Selected Publications
1
Swensen, J. et al. Continuous, real-time monitoring of cocaine in undiluted blood serum via a microfluidic electrochemical aptamer-based sensor. J. Am. Chem. Soc. 131, 4262–4266 (2009).
2
Ferguson, B.S. et al. Real-time, aptamer-based tracking of circulating therapeutic agents in living animals. Sci. Transl. Med. 5, 213ra165 (2013).
3
Wang, J.P. et al. Particle display: a quantitative screening method for generating high-affinity aptamers. Angew. Chem. Int. Ed. 53, 4796–4801 (2014)
4
Mage, P.L. et al. Closed-loop control of circulating drug levels in live animals. Nat. Biomed. Eng.1, 0070 (2017).
10 More

Join the movement

Building the future of always on, personalized healthcare takes the most ambitious and optimistic people. This is our life's work and if you want to make it yours too, we would love to hear from you.
Connect With Us
Disclaimer: This product is currently in development and has not yet been approved by the FDA. This product is not currently being offered for sale.
Privacy PolicyTerms of Service
© 2025 Adaptyx Biosciences, Inc.